NASDAQ:NARI Inari Medical (NARI) Stock Price, News & Analysis → Putin and other countries have a plan (From Whats On Finance) (Ad) Free NARI Stock Alerts $37.14 -0.79 (-2.08%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$36.81▼$38.3650-Day Range$37.93▼$59.0352-Week Range$36.73▼$71.85Volume1.53 million shsAverage Volume1.13 million shsMarket Capitalization$2.15 billionP/E RatioN/ADividend YieldN/APrice Target$73.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Inari Medical alerts: Email Address Inari Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside98.5% Upside$73.71 Price TargetShort InterestBearish8.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 13 Articles This WeekInsider TradingSelling Shares$1.95 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.21 out of 5 starsMedical Sector530th out of 910 stocksSurgical & Medical Instruments Industry60th out of 95 stocks 3.3 Analyst's Opinion Consensus RatingInari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInari Medical has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.06% of the float of Inari Medical has been sold short.Short Interest Ratio / Days to CoverInari Medical has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inari Medical has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInari Medical does not currently pay a dividend.Dividend GrowthInari Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NARI. Previous Next 1.9 News and Social Media Coverage News SentimentInari Medical has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Inari Medical this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for NARI on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,949,000.00 in company stock.Percentage Held by Insiders10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inari Medical are expected to grow in the coming year, from ($0.39) to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inari Medical is -1,238.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inari Medical is -1,238.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInari Medical has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Inari Medical Stock (NASDAQ:NARI)Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Read More NARI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NARI Stock News HeadlinesApril 19, 2024 | insidertrades.comInari Medical, Inc. (NASDAQ:NARI) Director Sells $58,040.00 in StockApril 19, 2024 | insidertrades.comMitch C. Hill Sells 6,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockApril 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 20, 2024 | americanbankingnews.comWilliam Hoffman Sells 1,451 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockApril 18, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the FirmApril 18, 2024 | investing.comInari Medical CFO sells shares worth $245,760April 17, 2024 | globenewswire.comInari Medical to Announce First Quarter 2024 Financial ResultsApril 14, 2024 | americanbankingnews.comInari Medical's (NARI) Buy Rating Reiterated at Canaccord Genuity GroupApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 11, 2024 | globenewswire.comInari Medical Announces the Release of 2023 Ethos and Sustainability ReportApril 10, 2024 | markets.businessinsider.comElucent Medical Secures Series C Funding to Advance Oncologic Surgery InnovationApril 2, 2024 | globenewswire.comInari Medical Strengthens Senior Leadership Team with Addition of Two ExecutivesMarch 30, 2024 | msn.comMarket Cap Game Show: Andy Cross vs. Bill MannMarch 25, 2024 | marketwatch.comInari Medical Shares Gain After Index MoveMarch 23, 2024 | morningstar.comInari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens BermanMarch 22, 2024 | markets.businessinsider.comForecasting The Future: 7 Analyst Projections For Inari MedicalMarch 20, 2024 | finance.yahoo.comDirector William Hoffman Sells 40,000 Shares of Inari Medical Inc (NARI)March 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Inari Medical, Inc. (NARI) and Encourages Investors with Losses to Contact the FirmMarch 19, 2024 | finance.yahoo.comNARI Apr 2024 65.000 callMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inari Medical, Inc.- NARIMarch 16, 2024 | investing.comInari Medical CFO sells shares worth over $250kMarch 16, 2024 | finanznachrichten.deInari Medical, Inc.: Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT RegistryMarch 12, 2024 | globenewswire.comInari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT RegistryMarch 12, 2024 | prnewswire.comNARI INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARIMarch 12, 2024 | prnewswire.comInari Medical Investigation: Kessler Topaz Meltzer & Check, LLP Investigates The Inari Medical, Inc. (NASDAQ: NARI) for Potential Securities ViolationsMarch 11, 2024 | businesswire.comInari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 11, 2024 | businesswire.comInari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsSee More Headlines Receive NARI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NARI CUSIPN/A CIK1531048 Webwww.inarimedical.com Phone877-923-4747FaxN/AEmployees1,300Year FoundedN/APrice Target and Rating Average Stock Price Target$73.71 High Stock Price Target$100.00 Low Stock Price Target$52.00 Potential Upside/Downside+94.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,640,000.00 Net Margins-0.33% Pretax Margin0.86% Return on Equity1.23% Return on Assets0.97% Debt Debt-to-Equity RatioN/A Current Ratio3.09 Quick Ratio2.52 Sales & Book Value Annual Sales$493.63 million Price / Sales4.45 Cash Flow$0.09 per share Price / Cash Flow437.66 Book Value$8.07 per share Price / Book4.70Miscellaneous Outstanding Shares57,960,000Free Float51,817,000Market Cap$2.20 billion OptionableOptionable Beta0.84 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Andrew J. Hykes (Age 50)CEO, President & Director Comp: $1.54MMr. Mitchell C. Hill (Age 65)Chief Financial Officer Comp: $864.63kDr. Thomas M. Tu M.D. (Age 51)Chief Medical Officer Comp: $865.63kMr. Paul A. Koehn (Age 61)Senior Vice President of Operations Mr. Kevin StrangeSenior Vice President of Finance, Accounting, Strategy & Business DevelopmentMr. John Hsu C.F.A.Vice President of Investor RelationsMs. Angela AhmadGeneral Counsel & SecretaryMr. Eric KhairySenior Vice President of MarketingMr. John R. Borrell (Age 57)Senior Vice President of Sales Ms. Tara DunnSenior VP & GM of LimFlowMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMNuVasiveNASDAQ:NUVAIntegra LifeSciencesNASDAQ:IARTPROCEPT BioRoboticsNASDAQ:PRCTView All CompetitorsInsiders & InstitutionsMaryland State Retirement & Pension SystemBought 18,475 shares on 4/20/2024Ownership: 0.032%State of Alaska Department of RevenueBought 25,566 shares on 4/19/2024Ownership: 0.054%Handelsinvest InvesteringsforvaltningSold 971 shares on 4/19/2024Ownership: 0.003%William HoffmanSold 1,451 sharesTotal: $58,040.00 ($40.00/share)Mitch C HillSold 6,000 sharesTotal: $245,760.00 ($40.96/share)View All Insider TransactionsView All Institutional Transactions NARI Stock Analysis - Frequently Asked Questions Should I buy or sell Inari Medical stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NARI shares. View NARI analyst ratings or view top-rated stocks. What is Inari Medical's stock price target for 2024? 6 analysts have issued 12 month price targets for Inari Medical's stock. Their NARI share price targets range from $52.00 to $100.00. On average, they expect the company's share price to reach $73.71 in the next year. This suggests a possible upside of 98.5% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts. How have NARI shares performed in 2024? Inari Medical's stock was trading at $64.92 on January 1st, 2024. Since then, NARI stock has decreased by 42.8% and is now trading at $37.14. View the best growth stocks for 2024 here. When is Inari Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our NARI earnings forecast. How can I listen to Inari Medical's earnings call? Inari Medical will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Inari Medical's earnings last quarter? Inari Medical, Inc. (NASDAQ:NARI) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The business earned $132.10 million during the quarter, compared to analysts' expectations of $131.82 million. Inari Medical had a positive trailing twelve-month return on equity of 1.23% and a negative net margin of 0.33%. The business's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) earnings per share. What ETFs hold Inari Medical's stock? ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Clough Select Equity ETF (CBSE), Invesco S&P SmallCap Health Care ETF (PSCH), Clough Long/Short Equity ETF (CBLS), Tema Cardiovascular and Metabolics ETF (HRTS), SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI). What guidance has Inari Medical issued on next quarter's earnings? Inari Medical issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $588.3 million. What other stocks do shareholders of Inari Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY). When did Inari Medical IPO? Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers. Who are Inari Medical's major shareholders? Inari Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.05%), Maryland State Retirement & Pension System (0.03%) and Handelsinvest Investeringsforvaltning (0.00%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman. View institutional ownership trends. How do I buy shares of Inari Medical? Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NARI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inari Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
